(19)
(11) EP 1 642 580 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.11.2009 Bulletin 2009/47

(45) Mention of the grant of the patent:
19.08.2009 Bulletin 2009/34

(21) Application number: 05021837.9

(22) Date of filing: 08.06.2000
(51) International Patent Classification (IPC): 
A61K 31/4745(2006.01)
C07D 471/02(2006.01)
A61K 31/47(2006.01)
 A61K 31/437(2006.01)
C07D 471/04(2006.01)

(54)

Sulfonamide substituted imidazoquinolines

Imidazoquinoline Sulfonamide

Sulfonamides d' imidazoquinoline

(84) Designated Contracting States:
GB

(30) Priority: 10.06.1999 US 138365 P
07.06.2000 US 589216

(43) Date of publication of application:
05.04.2006 Bulletin 2006/14

(62) Application number of the earlier application in accordance with Art. 76 EPC:
00938211.0 / 1198233

(73) Proprietor: Coley Pharmaceutical Group, Inc.
New York, N.Y. 10017-5755 (US)

(72) Inventors:
  • Crooks, Stephen L.
    Saint Paul, MN 55133-3427 (US)
  • Lindstrom, Kyle J.
    Saint Paul, MN 55133-3427 (US)
  • Merrill, Bryon A.
    Saint Paul, MN 55133-3427 (US)
  • Rice, Michael J.
    Saint Paul, MN 55133-3427 (US)

(74) Representative: Vossius & Partner 
Siebertstraße 4
81675 München
81675 München (DE)


(56) References cited: : 
WO-A-99/29693
   
  • PATENT ABSTRACTS OF JAPAN vol. 1999, no. 08, 30 June 1999 (1999-06-30) -& JP 11 080156 A (HOKURIKU SEIYAKU CO LTD), 26 March 1999 (1999-03-26)
  • VOSSIUS & PARTNER PATENTANWÄLTE: "Comparative Tests" INTERNET ARTICLE, [Online] 8 April 2005 (2005-04-08), pages 1-7, XP002366599 Retrieved from the Internet: URL:http://ofi.epoline.org/view/GetDossier > [retrieved on 2006-02-08]
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).